Theravance Biopharma Inc TBPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
-
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
-
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
-
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Trading Information
- Previous Close Price
- $16.98
- Day Range
- $16.91–17.02
- 52-Week Range
- $10.82–21.03
- Bid/Ask
- $16.93 / $17.00
- Shares Outstanding
- 51.83M
- Market Cap
- $877.45M
- Volume/Avg
- 868,561 / 538,445
Key Statistics
- Price/Earnings (Normalized)
- 16.84
- Price/Sales
- 8.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.02%
Company Profile
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 90
- Website
- https://www.theravance.com
Valuation
|
Metric
|
TBPH
|
|---|---|
Price/Earnings (Normalized) | 16.84 |
Price/Book Value | 3.02 |
Price/Sales | 8.04 |
Price/Cash Flow | 7.10 |
Price/Earnings
TBPH
Financial Strength
|
Metric
|
TBPH
|
|---|---|
Quick Ratio | 12.91 |
Current Ratio | 13.14 |
Interest Coverage | 69.57 |
Quick Ratio
TBPH
Profitability
|
Metric
|
TBPH
|
|---|---|
Return on Assets (Normalized) | 0.42% |
Return on Equity (Normalized) | 0.75% |
Return on Invested Capital (Normalized) | −2.41% |
Return on Assets
TBPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n?r@CgY | LOCK|$#lS | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|SCt&#%X | LOCK|cJ!S | $70B | |||
| argenx SE ADR
ARGX
| LOCK|ZQ&!v% | LOCK|#Gh | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hhn<LyJ | LOCK|w%S<< | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|n<L$^Vf | LOCK|Z% | $36B | |||
| Moderna Inc
MRNA
| LOCK|Fl%?Pq | LOCK|R% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v%MnTXCs | LOCK|gPR^F | $25B | |||
| Incyte Corp
INCY
| LOCK|$w!$<$m | LOCK|<rk | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qdT^<D | LOCK|^h | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|y&vG@c | LOCK|<%l | $17B |
United States